Abstracts

Topics for Abstract Allocation

Submit your research under one of the following scientific topics

1.1 Canine Leishmaniasis (CanL): New protocols for management, vaccine efficacy updates, and the impact of insecticide-impregnated collars/spot-on on public health.
1.2 Feline Leishmaniasis: Leishmania in cats and their role as secondary reservoirs.
1.3 Wildlife Reservoirs: The role of sylvatic cycles in the urbanization of leishmaniasis.
1.4 Zoonotic transmission cycles: In general.
1.5 One health approaches: In general.

2.1 Vector Competence, parasite development & Ecology: Impact of rising temperatures on sand fly phenology and distribution.
2.2 Vector Microbiome & Paratransgenesis: How the internal flora of the sand fly influences parasite development.
2.3 Insecticide Resistance: Monitoring and molecular mechanisms of resistance in Phlebotomus and Lutzomyia.
2.4 Sand fly taxonomy and systematics.
2.5 Vector genetics and genomics.
2.6 Climate change and vector distribution.

3.1 New Drug Discovery / Current treatment strategies: Target-based drug design and the repositioning of existing drugs.
3.2 Combination Therapies: Reducing toxicity and preventing the emergence of drug resistance.
3.3 Immunotherapy & Vaccines / Vaccine candidates: Progress in mRNA and DNA vaccines, and the use of immunomodulators alongside chemotherapy.
3.4 Leishmania-HIV Co-infection: Clinical management of complex cases and epidemiological updates.
3.5 Clinical aspects and trials: Cutaneous, visceral, mucocutaneous, PKDL and clinical complications and comorbidities.
3.6 Clinical trials of novel vaccines.
3.7 Vaccine Immunology.

4.1 Genomics, Transcriptomics & Gene Editing.
4.2 Proteomics & Metabolomics: Identifying new metabolic pathways for drug targeting.
4.3 Parasite Diversity & Taxonomy: Solving the "species complex" puzzles using molecular markers.
4.4 Parasite cell biology & metabolism.
4.5 Parasite virulence factors.
4.6 Drug resistance mechanisms.
4.7 Host-parasite molecular interactions.

5.1 Molecular Diagnostics: LAMP assays and CRISPR-based diagnostic tools.
5.2 Serological and Parasitological Diagnostics & Challenges.
5.3 Non-invasive Sampling: Saliva, urine, or skin-swab-based diagnostics to replace invasive biopsies.
5.4 The Point-of-Care / Rapid diagnostic techniques.
5.5 AI and Digital Health: AI-assisted microscopy and mobile health (mHealth) apps for leishmaniasis & monitoring.

6.1 Global Burden: WHO NTD roadmap targets and progress towards elimination.
6.2 Control & Elimination Programs: Case studies from Brazil, India, and the Mediterranean basin.
6.3 Drug Access & Policy: Ensuring equitable access to treatment in endemic low-income countries.
6.4 Environmental & Climate Drivers: Modeling the impact of climate change on disease distribution.
6.5 Surveillance systems and outbreak response.
6.6 Control program evaluation.

7.1 Innate Immune Evasion: How Leishmania manipulates macrophages and dendritic cells.
7.2 Adaptive Immunity & Memory: T-cell subsets and B-cell responses in protection vs. pathology.
7.3 Biomarkers of Protection: Identifying signatures of naturally acquired immunity.
7.4 Skin Immunity: The role of the skin microbiome and keratinocytes in early infection.
7.5 Immunopathology mechanisms.
7.6 Regulatory immune responses.

8.1 Cost-effectiveness of Interventions: Comparing the economic impact of different control strategies.
8.2 Socioeconomic Determinants: Poverty, migration, and conflict as drivers of leishmaniasis spread.
8.3 Community Engagement & Stigma: The social impact of disfiguring forms of leishmaniasis.
8.4 Equity & Access to Healthcare.
8.5 Global health policy and leishmaniasis.

9.1 Curriculum Development: Integrating leishmaniasis into medical, veterinary, and public health curricula.
9.2 E-learning and Digital Training Tools.
9.3 Capacity Building in Endemic Regions.
9.4 Scientific communication and knowledge translation.

Here you can download your Abstract Template:

Abstract Submission requires prior conference registration. For more information, go to the conference registration page.